State Medicaid Rate Updates Finally Moved in Elevance’s Favor
Elevance Health entered the third quarter with a problem familiar to every large Medicaid managed care organization: state payment rates had lagged the worsening health needs of the people enrolled in the program. In July, that dynamic started to shift. Several states delivered stronger-than-expected rate updates, and the insurer said the new pricing helped improve Medicaid performance enough to nudge its full-year outlook higher.
The change matters because Medicaid does not function like a standard commercial product. Payments are negotiated and regulated state by state, while the patient mix can swing quickly when policy changes, economic stress, or redeterminations alter enrollment. When healthier beneficiaries leave and sicker members remain, claims costs rise faster than the rates that are supposed to cover them. Elevance has spent much of 2025 managing that mismatch.
The company now expects its full-year Medicaid operating margin to come in slightly better than the -1.75% it had previously projected. Management still described 2026 as a trough year for Medicaid margins, with improvement more likely in 2027. Even so, the direction changed in a way investors had been waiting to hear: the business is no longer deteriorating at the same pace.
Medicaid Pressure, Then Partial Relief
Elevance covers 8.2 million Medicaid beneficiaries across more than a dozen states, so even small changes in rates or acuity can move earnings. Since 2024, the company has faced a tougher medical cost environment as the Medicaid population became sicker and more expensive to treat. State rate changes did not keep up, compressing margins for managed care organizations that depend on predictable reimbursement to cover acute, behavioral, and chronic care needs.
The insurer responded by exiting Washington, D.C.’s Medicaid market this summer and signaling that additional exits could follow through the end of 2027. Executive comments on the latest earnings call pointed to continued network tightening and selective market withdrawals as part of the response. In practical terms, the company is trimming exposure where the payment structure looks least sustainable and preserving capital where it sees a better fit between premiums and expected costs.
One-sentence reality check: Medicaid margin recovery will depend as much on state rate-setting as on anything Elevance can do internally.
Behavioral Health Costs Remain a Cost-Control Target
Elevance is also pushing on utilization that has been especially expensive. Behavioral healthcare, including applied behavioral analysis therapy for individuals with autism, remains one of the major cost drivers the company is trying to restrain. Those services are clinically important and often highly individualized, but they can also create material cost pressure when long-duration therapy use rises faster than expected.
From a payer perspective, the challenge is not simply whether the care is necessary. The challenge is whether the plan design, medical policy, and network structure can absorb the volume without losing financial balance. That is why management continues to talk about network actions and tighter management of high-cost categories rather than broad-based growth. The company’s strategy suggests a payer trying to re-establish pricing discipline after the post-pandemic Medicaid population shifted in a less favorable direction.
Better Government-Business Trends Lifted the Quarter
Elevance posted net income of $1.4 billion in the third quarter, up almost 15% year over year, even as revenue of $51.4 billion was essentially flat. The company’s medical loss ratio came in at 90.6%, down from 91.3% in the same quarter last year, reflecting better medical cost trends across its government businesses. That improvement matters because the ratio tracks how much of premium revenue is being spent on patient care rather than retained as margin.
The company’s health benefits division still delivered only $436 million in operating income, down 27% year over year and below analyst expectations. Management said that result would have been higher absent spending on operational investments, including member experience, medical cost management, dual-eligible growth, and quality initiatives. In other words, Elevance chose to put some of the upside back into the business rather than let it all flow through to short-term profit.
A separate Bright Spot appeared in Carelon, where operating income reached $908 million, up 17% year over year. That helped support the company’s broader results and contributed to the decision to raise 2026 guidance for adjusted diluted earnings per share, diluted earnings per share, and operating cash flow.
ACA and Medicare Advantage Added to the Upside
Medicaid was not the only line improving. Elevance said its individual Affordable Care Act business has retained more members than expected and now expects to end 2026 with at least 1.2 million ACA members, up from a prior expectation of 1 million. Deductible season had been expected to push costs higher in the back half of the year, but claims are developing more favorably than anticipated so far. The company now expects a modestly higher full-year operating margin in that segment as well.
Medicare Advantage also contributed to the quarter. Seniors in Elevance’s MA plans are more profitable this year after the company trimmed underperforming products and leaned harder into HMOs, which generally use narrower provider networks. For 2027, the insurer plans to keep emphasizing HMOs and dual-eligible members, a mix management believes better supports its target margin range.
These moves reflect a consistent portfolio strategy: concentrate on products and geographies where pricing, network design, and member risk are easier to manage. In payer terms, that means less tolerance for lines of business that consume more capital than they return.
Policy Risk Still Looms Over 2027 and Beyond
Even with the stronger quarter, Medicaid still faces policy turbulence. The GOP’s “Big Beautiful Bill,” passed last summer, includes changes that executives have described as largely manageable, including a work requirement linked to Medicaid eligibility. The real unknown lies in how states will implement those requirements and how quickly the effects will show up in enrollment, acuity, and rates.
Felicia Norwood, Elevance’s chief health benefits officer, said states are still making decisions that could reshape how many members remain in the program and how much the company is paid to cover them. Some states are already considering how work requirements may leave behind a smaller but sicker Medicaid population, which would affect 2027 pricing. State-by-state variation is likely to be decisive here, because Medicaid is not one national risk pool but a patchwork of local actuarial decisions.
Executives said they are encouraged by some of the 2027 rate signals they are seeing, but final implementation of community engagement requirements will determine whether those rates are enough. Until then, Medicaid remains the business line most exposed to policy, utilization, and state budget choices all at once.
Leadership Changes at Carelon Add Another Layer
Elevance also announced that Jeff Park will become president of Carelon in December. Park brings more than two decades of experience in healthcare and pharmacy, and he arrives from Waltz Health, where he served as president. He succeeds Mark Kaye in the role.
For a company trying to control costs, sharpen product selection, and keep government business on firmer footing, leadership continuity in its services arm matters. Carelon has become part of the operational engine behind the broader enterprise, and the next phase of Medicaid management will depend on whether those support businesses can keep improving medical cost performance without sacrificing member access or quality. The quarter showed progress, but the next test will be whether July’s rate relief lasts long enough to stabilize 2027 pricing decisions.